Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/193936
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer’s disease pathogenesis

AutorEsteve, Pilar CSIC ORCID; Rueda-Carrasco, Javier; Mateo, María I.; Martín-Bermejo, María Jesús CSIC; Draffin, Jonathan E. CSIC ORCID; Pereyra, Guadalupe; Sandonís, África; Crespo, Inmaculada; Moreno, Inmaculada CSIC ORCID; Aso, Ester; García-Esparcia, Paula; Gómez-Tortosa, Estrella; Rábano, Alberto; Fortea, Juan; Alcolea, Daniel; Lleó, Alberto; Heneka, Michael T.; Valpuesta, José M. CSIC ORCID ; Esteban, José A. CSIC ORCID; Ferrer, Isidro; Domínguez, Mercedes; Bovolenta, Paola CSIC ORCID
Fecha de publicaciónago-2019
CitaciónNature Neuroscience
ResumenThe deposition of aggregated amyloid-β peptides derived from the pro-amyloidogenic processing of the amyloid precurson protein (APP) into characteristic amyloid plaques (APs) is distinctive to Alzheimer’s disease (AD). Alternative APP processing via the metalloprotease ADAM10 prevents amyloid-β formation. We tested whether downregulation of ADAM10 activity by its secreted endogenous inhibitor secreted-frizzled-related protein 1 (SFRP1) is a common trait of sporadic AD. We demonstrate that SFRP1 is significantly increased in the brain and cerebrospinal fluid of patients with AD, accumulates in APs and binds to amyloid-β, hindering amyloid-β protofibril formation. Sfrp1 overexpression in an AD-like mouse model anticipates the appearance of APs and dystrophic neurites, whereas its genetic inactivation or the infusion of α-SFRP1-neutralizing antibodies favors non-amyloidogenic APP processing. Decreased Sfrp1 function lowers AP accumulation, improves AD-related histopathological traits and prevents long-term potentiation loss and cognitive deficits. Our study unveils SFRP1 as a crucial player in AD pathogenesis and a promising AD therapeutic target.
Versión del editor10.1038/s41593-019-0432-1
URIhttp://hdl.handle.net/10261/193936
ISSN1097-6256
Aparece en las colecciones: (CBM) Artículos
(CNB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
BovolentaP_ElevatedLevelsofSecreted.pdfArticulo principal1,73 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

Page view(s)

343
checked on 18-mar-2024

Download(s)

826
checked on 18-mar-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.